Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Embera NeuroTherapeutics, Inc. |
---|---|
Information provided by: | Embera NeuroTherapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT00567814 |
Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be questioned regarding drug craving and mood symptoms.
Condition | Intervention |
---|---|
Cocaine Dependence Cocaine Addiction |
Drug: Metyrapone Drug: Oxazepam Drug: Placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction |
Estimated Enrollment: | 45 |
Study Start Date: | December 2007 |
Study Completion Date: | November 2008 |
Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Lower dose combination of metyrapone with oxazepam
|
Drug: Metyrapone
Twice daily
Drug: Oxazepam
Twice Daily
|
2: Active Comparator
Higher dose combination of metyrapone with oxazepam
|
Drug: Metyrapone
Twice daily
Drug: Oxazepam
Twice Daily
|
3: Placebo Comparator |
Drug: Placebo
Twice daily
|
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Louisiana | |
Department of Psychiatry, Psychopharmacology Research Clinic | |
Shreveport, Louisiana, United States, 71103 |
Principal Investigator: | Anita S Kablinger, MD | LSU Health Sciences Center - Shreveport |
Responsible Party: | Embera NeuroTherapeutics, Inc. ( Marie Lindner, MD/Medical Monitor ) |
Study ID Numbers: | ECA-001 |
Study First Received: | December 3, 2007 |
Last Updated: | December 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00567814 |
Health Authority: | United States: Institutional Review Board |
Cocaine Dependence Addiction Cortisol GABA |
Cocaine-Related Disorders Behavior, Addictive Hydrocortisone Cortisol succinate Oxazepam Disorders of Environmental Origin Impulsive Behavior |
Compulsive Behavior Dopamine Metyrapone Mental Disorders Substance-Related Disorders Hydrocortisone acetate Cocaine |
Antimetabolites Dopamine Uptake Inhibitors Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Tranquilizing Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Anesthetics Central Nervous System Depressants Enzyme Inhibitors |
Cardiovascular Agents Pharmacologic Actions Anesthetics, Local Sensory System Agents Therapeutic Uses Hypnotics and Sedatives Vasoconstrictor Agents GABA Agents Anti-Anxiety Agents Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |